VHL and kidney neoplasm: For the selection of therapy in VHL patients with kidney tumors, most respondents (87%) preferred to initiate belzutifan in individuals where local treatment would cause significant morbidity, and up to 54% considered starting belzutifan as the primary treatment for lesions meeting the size threshold for intervention.